These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 7610837)
41. A change in the study evaluation paradigm reveals that larynx preservation compromises survival in T4 laryngeal cancer patients. Dyckhoff G; Plinkert PK; Ramroth H BMC Cancer; 2017 Sep; 17(1):609. PubMed ID: 28863776 [TBL] [Abstract][Full Text] [Related]
43. Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro. Jaakkola M; Rantanen V; Grénman S; Kulmala J; Grénman R Anticancer Res; 1997; 17(2A):939-43. PubMed ID: 9137431 [TBL] [Abstract][Full Text] [Related]
44. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol. Abitbol A; Abdel-Wahab M; Lewin A; Troner M; Rodrigues MA; Hamilton-Nelson KL; Markoe A Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):942-7. PubMed ID: 12095561 [TBL] [Abstract][Full Text] [Related]
45. Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas. Nishimura G; Tsukuda M; Horiuchi C; Satake K; Yoshida T; Nagao J; Kawakami M; Kondo N; Arai Y; Taguchi T; Matsuda H; Mikami Y Auris Nasus Larynx; 2007 Dec; 34(4):499-504. PubMed ID: 17604583 [TBL] [Abstract][Full Text] [Related]
46. Taxol and radiation. Geard CR; Jones JM; Schiff PB J Natl Cancer Inst Monogr; 1993; (15):89-94. PubMed ID: 7912535 [TBL] [Abstract][Full Text] [Related]
47. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Gupta N; Hu LJ; Deen DF Int J Radiat Oncol Biol Phys; 1997 Mar; 37(4):885-95. PubMed ID: 9128966 [TBL] [Abstract][Full Text] [Related]
48. [Chemotherapy guidance of the drug sensitivity test in vitro in human laryngeal squamous cell carcinoma]. Zhang S; Kong W Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Aug; 20(15):711-3. PubMed ID: 17037023 [TBL] [Abstract][Full Text] [Related]
49. [Carcinoma of the larynx: palliative radiotherapy]. Vitale V; Corvò R Acta Otorhinolaryngol Ital; 1991; 11 Suppl 33():95-7. PubMed ID: 1718140 [No Abstract] [Full Text] [Related]
50. Vascular endothelial growth factor-targeted paclitaxel-loaded liposome microbubbles and inhibition of human epidermoid-2 cell proliferation. Zhou L; Luo W Head Neck; 2017 Apr; 39(4):656-661. PubMed ID: 28106938 [TBL] [Abstract][Full Text] [Related]
51. Unexpected radiation laryngeal necrosis after carbon ion therapy using conventional dose fractionation for laryngeal cancer. Demizu Y; Fujii O; Nagano F; Terashima K; Jin D; Mima M; Oda N; Takeuchi K; Takeda M; Ito K; Fuwa N; Okimoto T Jpn J Clin Oncol; 2015 Nov; 45(11):1076-81. PubMed ID: 26355161 [TBL] [Abstract][Full Text] [Related]
52. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. Rosenthal DI; Lee JH; Sinard R; Yardley DA; Machtay M; Rosen DM; Egorin MJ; Weber RS; Weinstein GS; Chalian AA; Miller LK; Frenkel EP; Carbone DP J Clin Oncol; 2001 Mar; 19(5):1363-73. PubMed ID: 11230480 [TBL] [Abstract][Full Text] [Related]
53. Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma. Wang S; Akhtar J; Wang Z Tumour Biol; 2015 Sep; 36(10):7797-806. PubMed ID: 25944168 [TBL] [Abstract][Full Text] [Related]
55. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Terzis AJ; Thorsen F; Heese O; Visted T; Bjerkvig R; Dahl O; Arnold H; Gundersen G Br J Cancer; 1997; 75(12):1744-52. PubMed ID: 9192976 [TBL] [Abstract][Full Text] [Related]
56. Radiotherapy for laryngeal squamous cell carcinoma: current standards. Dirix P; Lambrecht M; Nuyts S Expert Rev Anticancer Ther; 2010 Sep; 10(9):1461-9. PubMed ID: 20836681 [TBL] [Abstract][Full Text] [Related]
57. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Tsurumaru M Dis Esophagus; 2004; 17(4):338-44. PubMed ID: 15569374 [TBL] [Abstract][Full Text] [Related]
58. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer]. Tang X; Lu M; Li C; Deng S; Li M Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734 [TBL] [Abstract][Full Text] [Related]
59. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Aisner J; Belani CP; Kearns C; Conley B; Hiponia D; Engstrom C; Zuhowski E; Egorin MJ Semin Oncol; 1995 Oct; 22(5 Suppl 12):17-21. PubMed ID: 7481856 [TBL] [Abstract][Full Text] [Related]
60. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line. Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]